Targacept has announced that AstraZeneca will pursue the development of the company’s candidate AZD1446 as a treatment for Alzheimer’s disease.
AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor developed through a research collaboration conducted by Targacept and AstraZeneca.
Go deeper with GlobalData
Under the terms of a 2005 collaborative research and license agreement, AstraZeneca took responsibility for further development and potential commercialisation of AZD1446.
The drug will now move into a Phase II trial as an additional treatment to donepezil for patients with mild to moderate Alzheimer’s.
Targacept President and CEO J Donald deBethizy said that the planned evaluation of AZD1446 as an augmentation treatment in Alzheimer’s complements Targacept’s ongoing Phase IIb study of AZD3480 as a monotherapy.
See Also:
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
